Nitazoxanide

Antiprotozoal — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Nitazoxanide is an ofp drug in the Antiprotozoal class catalogued in DrugCentral. It was first approved by the FDA in 2002. DrugCentral lists 9 molecular targets, including ANO1, HDAC6 and AKR1B1. Recorded indications include Giardiasis and Infection by Cryptosporidium.

• Approval status: ofp (first approved 2002 by the FDA).
• Drug class: Antiprotozoal.
• Molecular targets: ANO1, HDAC6, AKR1B1 and STAT3 (9 listed in DrugCentral).
• Indications: Giardiasis and Infection by Cryptosporidium.
• ATC code: J01RA17 (Combinations of antibacterials).
• Molecular formula: C12H9N3O5S; molecular weight 307.28 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Giardiasis
• Infection by Cryptosporidium

Off-label uses (1)

• Coronavirus infection

Contraindications (3)

• Diabetes mellitus
• Disease of liver
• Kidney disease

Mechanism & targets

• Established pharmacologic class: Antiprotozoal

Molecular targets (9)

Target	Gene	Action	Activity
Anoctamin-1	ANO1	unknown	IC50 6.37
Histone deacetylase 6	HDAC6	unknown	IC50 6.00
Aldose reductase	AKR1B1	unknown	IC50 5.09
Signal transducer and activator of transcription 3	STAT3	unknown	IC50 5.01
Replicase polyprotein 1ab	REP	unknown	IC50 5.01
Pyruvate-flavodoxin oxidoreductase	—	unknown	Ki 4.98
Trehalose-binding lipoprotein LpqY	lpqY	unknown	Kd 4.07
Pyruvate:ferredoxin oxidoreductase	—	inhibitor	—
Pyruvate dehydrogenase [NADP(+)]	PFOR	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2002-11-22	FDA	—	ROMARK	Yes

ATC classification

ATC code	Therapeutic hierarchy
J01RA17	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials
P01AX11	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES › Other agents against amoebiasis and other protozoal diseases

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Chromaturia	91.5
Diarrhoea	77.4
Parasitic gastroenteritis	63.6
Anticholinergic syndrome	46.9
Scleral discolouration	39.5
Cryptosporidiosis infection	37.2
Choriomeningitis lymphocytic	34.8

Chemical structure

• Molecular formula: C₁₂H₉N₃O₅S
• Molecular weight: 307.28 g/mol
• CAS number: 55981-09-4
• InChIKey: YQNQNVDNTFHQSW-UHFFFAOYSA-N
• PubChem CID: 41684

CC(=O)OC1=C(C=CC=C1)C(=O)NC1=NC=C(S1)[N+]([O-])=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nitazoxanide used for?

DrugCentral lists the following indications for Nitazoxanide: Giardiasis and Infection by Cryptosporidium.

How does Nitazoxanide work?

Its molecular targets in DrugCentral include ANO1, HDAC6, AKR1B1 and STAT3.

When was Nitazoxanide first approved?

Nitazoxanide was first approved by the FDA in 2002.

What drug class does Nitazoxanide belong to?

Nitazoxanide is in the Antiprotozoal class.

What is the chemical formula of Nitazoxanide?

Nitazoxanide has the molecular formula C12H9N3O5S and a molecular weight of 307.28 g/mol.

Sources

• DrugCentral drug card 1943 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1401 — compound record and bioactivity
• PubChem CID 41684 — chemical identifiers
• DrugBank DB00507 — drug record
• FDA UNII SOA12P041N — substance identity
• DailyMed: FDA labels for Nitazoxanide — current prescribing information (label search)
• UniProt Q5XXA6 (ANO1) — target protein
• UniProt Q9UBN7 (HDAC6) — target protein
• UniProt P15121 (AKR1B1) — target protein
• UniProt P40763 (STAT3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.